Research Topics
| R S KeefeSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationaleRichard S E Keefe
Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
Schizophr Bull 29:45-55. 2003....- Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophreniaR S Keefe
Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
Arch Gen Psychiatry 54:169-76. 1997..We investigated whether these hypothesized components of a schizophrenia-related phenotype are associated with one another or are independent in nonpsychotic relatives of patients with schizophrenia... - Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatmentP D Harvey
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
Am J Psychiatry 158:176-84. 2001..The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice... - Severity of symptoms in chronically institutionalized geriatric schizophrenic patientsM Davidson
Department of Psychiatry, Mount Sinai School of Medicine, New York
Am J Psychiatry 152:197-207. 1995.... - Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trialRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
Neuropsychopharmacology 33:1217-28. 2008..A significant and surprisingly large placebo/practice effect was observed among placebo-treated patients, and is a serious consideration in future clinical trial study designs for potential cognitive enhancing compounds in schizophrenia... - Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparisonRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
Am J Psychiatry 164:1061-71. 2007..The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis... 
How should DSM-V criteria for schizophrenia include cognitive impairment?Richard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3270, Durham, NC 27710, USA
Schizophr Bull 33:912-20. 2007..Given the current emphasis on the development of cognitive treatments, the evaluation of cognition in schizophrenia is an essential component of mental health education...- Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialRichard S E Keefe
Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
Arch Gen Psychiatry 64:633-47. 2007..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined... - AKT1 and neurocognition in schizophreniaAndrea Poyastro Pinheiro
Department of Psychiatry, University of North Carolina at Chapel Hill, NC, USA
Aust N Z J Psychiatry 41:169-77. 2007..Therefore, the association of genetic variation in AKT1 with neurocognition was investigated in patients with schizophrenia... - Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patientsMarie Cecile Bralet
Department of Psychiatry Fitz James 5, Clermont de l Oise, Mental Health Hospital, 2 rue des Finets, 60600 Clermont de l Oise, France
Eur Psychiatry 22:365-70. 2007.... - Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE studyMarvin S Swartz
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
Am J Psychiatry 164:428-36. 2007..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia... - Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE studyT Scott Stroup
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
Am J Psychiatry 164:415-27. 2007..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine... - Risperidone and cognitive function in children with disruptive behavior disordersGahan J Pandina
Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
Biol Psychiatry 62:226-34. 2007..Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed... - Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaRobert A Rosenheck
University of North Carolina, Chapel Hill, USA
Am J Psychiatry 163:2080-9. 2006..Second-generation antipsychotics have largely replaced first-generation antipsychotics for the treatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted... - Cognition as an outcome measure in schizophreniaMichael S Kraus
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina 27710, USA
Br J Psychiatry Suppl 50:s46-51. 2007..Cognitive deficits are a core feature of schizophrenia. These deficits are not caused by medication or symptoms, and have a dramatic negative effect on real-world functioning... 
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization StudyMichael F Green
Semel Institute for Neuroscience and Human Behavior, UCLA, 300 Medical Plaza, Rm 2263, Los Angeles, CA 90095 6968, USA
Am J Psychiatry 165:221-8. 2008..e., a co-primary) that is considered functionally meaningful. The goal of the current study was to describe steps to evaluate four potential co-primary measures for psychometric properties and validity...- Implementation considerations for multisite clinical trials with cognitive neuroscience tasksRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3270, Durham, NC 27710, USA
Schizophr Bull 34:656-63. 2008..Suggestions for overcoming these implementation challenges are offered... - Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)Richard S E Keefe
Department of Psychiatry, Box 3207, Duke University Medical Center, Durham, North Carolina 27710, USA
Schizophr Res 102:108-15. 2008..An education-correction factor was calculated and recommended only for non-schizophrenia patients. Eight different verbal memory tests were found to have equivalent levels of difficulty... - What CATIE found: results from the schizophrenia trialMarvin S Swartz
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
Psychiatr Serv 59:500-6. 2008..Patient characteristics and clinical circumstances affected drug effectiveness; these patient factors are important in making treatment choices... - Relationship of cognition and psychopathology to functional impairment in schizophreniaSomaia Mohamed
New England Mental Illness, Research, Education and Clinical Center, Department of Veterans Affairs, West Haven, Conn 06516, USA
Am J Psychiatry 165:978-87. 2008..This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)... - The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognitionJames J Crowley
Department of Genetics, University of North Carolina at Chapel Hill, North Carolina 27599 7264, USA
Am J Med Genet B Neuropsychiatr Genet 147:1298-300. 2008..We were unable to replicate previous associations of rs6994992 with schizophrenia and, moreover, did not find significant associations with age of onset, an estimate of pre-morbid IQ, or neurocognition... - Cognitive deficits in patients with schizophrenia: effects and treatmentRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
J Clin Psychiatry 68:8-13. 2007..Therefore, cognitive deficits should be included in the diagnostic criteria for schizophrenia. Clinicians need to focus treatment options on helping patients to regain premorbid levels of cognitive functioning... - Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophreniaS Kristian Hill
Center for Cognitive Medicine, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA
J Int Neuropsychol Soc 14:209-21. 2008.... - Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophreniaSandra G Resnick
New England Mental Illness Research Education and Clinical Center, Yale University School of Medicine, VA Connecticut Health Care System, NEPEC 182, 950 Campbell Ave, West Haven, CT 06516, USA
J Behav Health Serv Res 35:215-25. 2008..Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine... - The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validityKeith H Nuechterlein
Department of Psychology, UCLA Semel Institute for Neuroscience and Human Behavior, 300 Medical Plaza, Rm 2251, Los Angeles, CA 90095 6968, USA
Am J Psychiatry 165:203-13. 2008.... - The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardizationRobert S Kern
Department of Psychology, Geffen School of Medicine, University of California, Los Angeles CA 90073, USA
Am J Psychiatry 165:214-20. 2008..S. community sample with the battery administered as a unit... - A longitudinal study of neurocognitive function in individuals at-risk for psychosisRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
Schizophr Res 88:26-35. 2006..The time course and predictive value of cognitive deficits in the development of psychosis has not been established... - Sensory acuity and reasoning in delusional disorderCharles R Conway
Duke University Department of Psychiatry, John Umstead Hospital, Butner, NC 27509, USA
Compr Psychiatry 43:175-8. 2002..Further, the study suggests that this reasoning difference generalizes to events outside the DD subjects' delusional realm and can be evoked in an experimental environment... - Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
Biol Psychiatry 59:97-105. 2006..Neurocognitive deficits are severe in first-episode psychosis... - A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophreniaRobert W Buchanan
Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
Schizophr Bull 31:5-19. 2005.... - Antipsychotic drug effects on brain morphology in first-episode psychosisJeffrey A Lieberman
Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Arch Gen Psychiatry 62:361-70. 2005..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia... - Defining a cognitive function decrement in schizophreniaRichard S E Keefe
Duke University, School of Medicine, Durham, North Carolina, USA
Biol Psychiatry 57:688-91. 2005.... - Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteriaMichael F Green
Neuropsychiatric Institute, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
Biol Psychiatry 56:301-7. 2004..The results from this meeting constitute the initial steps for reaching a consensus cognitive battery for clinical trials in schizophrenia... - Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidolRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
Am J Psychiatry 161:985-95. 2004..This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis... - The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive batteryRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
Schizophr Res 68:283-97. 2004..76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement... - Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illnessPhilip D Harvey
Mt Sinai School of Medicine, 1425 Madison Avenue, New York, N Y 10029, USA
J Clin Psychiatry 65:361-72. 2004..Thus, a much wider range of improvements, not widely produced by previous treatments, is required to take treatment for schizophrenia to a new level of effectiveness... - Source monitoring improvement in patients with schizophrenia receiving antipsychotic medicationsRichard S E Keefe
Duke University Medical Center, Box 3270, Durham, NC 27710, USA
Psychopharmacology (Berl) 169:383-9. 2003.... - Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sourcesRichard S E Keefe
Department of Psychiatry and Behavioural Science, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
Schizophr Res 57:51-67. 2002..This deficit, termed autonoetic agnosia, may result in the conclusion that self-generated thoughts come from an external source... - Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller
University of Iowa Carver College of Medicine, Psychiatry Research, 2 105 MEB, 500 Newton Rd, Iowa City, IA 52242 1000, USA
Schizophr Res 80:33-43. 2005..To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment... - Effectiveness of antipsychotic drugs in patients with chronic schizophreniaJeffrey A Lieberman
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
N Engl J Med 353:1209-23. 2005..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study... - Insight in first-episode psychosisJoseph P McEvoy
John Umstead Hospital, Duke University Department of Psychiatry, Butner, NC 27509, USA
Psychol Med 36:1385-93. 2006.... - Baseline neurocognitive deficits in the CATIE schizophrenia trialRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
Neuropsychopharmacology 31:2033-46. 2006..Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity... - Optimization of a multinomial model for investigating hallucinations and delusions with source monitoringTodd S Woodward
Department of Research, Riverview Hospital, Coquitlam, Canada
Schizophr Res 85:106-12. 2006..Statistical and cognitive interpretations of the findings are discussed... - Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychoticT Scott Stroup
Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
Am J Psychiatry 163:611-22. 2006..This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic... - Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatmentJoseph P McEvoy
Clinical Research Service, John Umstead Hospital, 1003 12th St, Bldg 32, Butner, NC 27705, USA
Am J Psychiatry 163:600-10. 2006.... - The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacityRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
Am J Psychiatry 163:426-32. 2006..This study describes the reliability and validity of a new interview-based assessment of cognition, the Schizophrenia Cognition Rating Scale (SCoRS), that involves interviews with patients and informants... - The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcomeRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
J Clin Exp Neuropsychol 28:260-9. 2006..They also suggest that the measures being considered as potential co-primary indicators of cognitive function for registration trials are significantly correlated with cognition as assessed by brief cognitive assessments... - Measuring outcome priorities and preferences in people with schizophreniaRobert Rosenheck
Northeast Program Evaluation Center 182, VA Connecticut Health Care System, 950 Campbell Avenue, West Haven, CT 06516, USA
Br J Psychiatry 187:529-36. 2005..Measures have not taken account of the relative importance patients place on various outcomes... - One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophreniaRichard S E Keefe
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
Schizophr Res 81:1-15. 2006..Haloperidol-treated patients improved only on domains of learning/memory. However, patients able to remain in treatment for the entire 52 weeks benefited more from olanzapine or risperidone treatment than haloperidol treatment... - NCAM1 and neurocognition in schizophreniaPatrick F Sullivan
Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599 7264, USA
Biol Psychiatry 61:902-10. 2007..Neural cell adhesion molecule 1 (NCAM1, aliases NCAM and CD56) may be a candidate gene for schizophrenia or for neurocognition in schizophrenia as supported by linkage and functional findings... - The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer
VA San Diego Healthcare System, USA
Schizophr Res 80:9-18. 2005.... - Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trialMiranda H Chakos
Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn, 11572, USA
Psychiatr Serv 57:1094-101. 2006..CONCLUSIONS: Concomitant use of psychotropic medications to treat people with schizophrenia is common. Empirical data demonstrating the effectiveness of many of these agents for this population are lacking...